Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
0.64
+0.01 (+0.79%)
Latest market quote · 2026-09-23 20:00 (UTC)
Company profile
Healthcare
Biotechnology
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Company websiteIssued common shares
Shares available to trade
Price relative to trailing earnings
Sensitivity relative to the market
Mean published price target
Reported full-time workforce
Shares held by institutions
Shares held by company insiders
Current session activity
High-to-low move
Share of advancing days
Based on daily returns
Versus provisional U.S. equity benchmark
Annualized negative-return risk
Historical one-day loss threshold
Latest coverage
Zacks · Sep 1, 2026
MT Newswires · Jul 28, 2026
MT Newswires · Jul 28, 2026
Zacks · Jul 13, 2026
Reader research
Join the discussion
Log in to share sentiment, a price target, and your investment thesis.
Log in to commentLargest one-day advance
Largest one-day decline
Largest one-year decline
Low-to-high range position
Shares sold short
Percent of public float
Short-interest ratio
Nearest-expiry open interest
Price, momentum, breadth and range
Scores are technical indicators derived from the available one-year price history and are not investment recommendations. Short-interest and options figures display when supplied by the market-data provider.
Zacks · Jul 13, 2026